InvestorsHub Logo
Followers 8
Posts 389
Boards Moderated 0
Alias Born 02/12/2009

Re: exwannabe post# 243746

Wednesday, 11/25/2015 10:22:29 PM

Wednesday, November 25, 2015 10:22:29 PM

Post# of 345597
ex,

To be clear when you said:

...do not forget that many patients are likely now on Opdivo that showed 17 months OS


Opdivo did not have a 17 month OS. I've posted this to you before with the links to the data and I do so again in hopes that you stop providing incorrect information or you can take the time and correct me; which to date you haven't seen the need to.

According to the FDA, what Opdivo did was that for the 19% of patients in the trial that had an ORR (ORR consists of partial and complete responses), the response lasted for an average of 17 months. Therefore, every time you say Opdivo has an OS of 17 months, I believe it is misleading. There is no such statistic that was ever published by BMS or the FDA. To repeat the 17 months number was the AVERAGE duration of response for ONLY the 19% of the population that had an ORR. The ONLY OS number published was the MOS number of 12.2 months which is representative of the entire trial population, not just a cherry picked subset.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News